Mankind Pharma has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a standalone net profit of ₹2,037.56 crore for the year, while the consolidated net profit reached ₹1,938.10 crore. The Board also approved key strategic initiatives, including an additional investment of ₹500 crore in its subsidiary, Mankind Medicare Private Limited, and the re-appointment of its Whole-Time Director, Mr. Satish Kumar Sharma.
Financial Performance Overview
For the financial year ended March 31, 2026, Mankind Pharma demonstrated robust performance. On a standalone basis, the company achieved total revenue of ₹10,421.18 crore and a profit of ₹2,037.56 crore. On a consolidated basis, the group reported total revenue of ₹14,277.64 crore and a net profit attributable to equity holders of ₹1,912.93 crore. The results highlight the company’s sustained growth and operational efficiency throughout the fiscal year.
Strategic Investments and Corporate Updates
The Board of Directors has approved an additional investment of up to ₹500 crore in Mankind Medicare Private Limited, a wholly-owned subsidiary. These funds are earmarked for capacity expansion and the development of new manufacturing facilities. Additionally, the company has announced the re-appointment of Mr. Satish Kumar Sharma as a Whole-Time Director for a fresh term of 5 years, effective September 23, 2026.
Leadership and Governance Changes
The Board acknowledged the resignation of Mr. Pramod Gokhale, the Global Chief Information Officer, effective from the close of business hours on May 31, 2026. Furthermore, the company reported a noteworthy decision by its executive leadership—Mr. Ramesh Juneja (Executive Chairman), Mr. Rajeev Juneja (Vice Chairman & Managing Director), and Mr. Sheetal Arora (CEO & Whole Time Director)—who have opted to forgo their commission for the 2025-26 financial year to bolster the company’s cash position for future expansion.
Source: BSE
